Focus Rheums| Dr. Jekyll or Mr. Hyde? (video)

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Anifrolumab Promising for SLE

  |  Issue: February 2020, January 2020  |  

Although the study did not achieve its primary endpoint, improvements associated with clinical benefits of anifrolumab were observed in many of the secondary endpoints. The 300 mg anifrolumab dose suppressed the interferon gene signature and was generally well tolerated.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Furie R, Morand E, Bruce I, et al. A phase 3 randomized controlled trial of anifrolumab in patients with moderate to severe systemic lupus erythematosus (abstract 1763). Arthritis Rheumatol. 2019 Oct;71(suppl 10).

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus

    ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…

    Interferon Score Predicts AI-CTDs

    People with autoimmune connective tissue diseases produce antibodies against nuclear antigens up to 10 years before they develop clinical features. Anti-nuclear antibodies (ANAs) are also very common, and a small percentage of ANA-positive patients progress to clinical autoimmunity. The question: Is there a reliable way to screen at-risk patients before they develop active autoimmunity and…

    An Evidence-Based Drug Update & Guidance for Rheumatologists

    ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…